Sustainable Development Goals
Abstract/Objectives
Boron neutron capture therapy (BNCT) is a promising treatment modality for patients diagnosed with malignant brain tumors. It is currently used for emergency and compassionate purposes to treat end-stage malignant glioma or recurrent head and neck cancer patients in Taiwan. Understanding the factors influencing treatment response is crucial for optimizing patient care. This study aimed to investigate the association between tumor response and various parameters in end-stage malignant glioma patients following BNCT.
Results/Contributions

The results indicate that BNCT effectively reduces tumor volume, with three patients achieving complete response and ten patients attaining partial response, resulting in an objective response rate of up to 80%. The median overall survival period is 9 months, and the levels of circulating myeloid-derived suppressor cells (MDSC) may serve as an indicator for predicting treatment response. This clinical study demonstrates that BNCT can improve the quality of life and extend survival for patients with advanced glioblastoma.

References
Contact Information
江啓勳
cschiang@mx.nthu.edu.tw